Literature DB >> 26880225

Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans.

Matthew W Johnson1, Katherine A MacLean2, Michael J Caspers3, Thomas E Prisinzano3, Roland R Griffiths4.   

Abstract

Salvinorin A is a kappa opioid agonist and the principal psychoactive constituent of the Salvia divinorum plant, which has been used for hallucinogenic effects. Previous research on salvinorin A pharmacokinetics likely underestimated plasma levels typically resulting from the doses administered due to inefficient vaporization and not collecting samples during peak drug effects. Six healthy adults inhaled a single high dose of vaporized salvinorin A (n = 4, 21 mcg/kg; n = 2, 18 mcg/kg). Participant- and monitor-rated effects were assessed every 2 min for 60 min post-inhalation. Blood samples were collected at 13 time points up to 90 min post-inhalation. Drug levels peaked at 2 min and then rapidly decreased. Drug levels were significantly, positively correlated with participant and monitor drug effect ratings. Significant elevations in prolactin were observed beginning 5 min post-inhalation and peaking at 15 min post-inhalation. Cortisol showed inconsistent increases across participants. Hormonal responses were not well correlated with drug levels. This is the first study to demonstrate a direct relationship between changes in plasma levels of salvinorin A and drug effects in humans. The results confirm the efficacy of an inhalation technique for salvinorin A.
© The Author(s) 2016.

Entities:  

Keywords:  Salvia divinorum; cortisol; endocrine; pharmacokinetics; prolactin; salvinorin A

Mesh:

Substances:

Year:  2016        PMID: 26880225      PMCID: PMC5289219          DOI: 10.1177/0269881116629125

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  24 in total

Review 1.  Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor.

Authors:  Douglas J Sheffler; Bryan L Roth
Journal:  Trends Pharmacol Sci       Date:  2003-03       Impact factor: 14.819

2.  The effects of spiradoline (U-62066E), a kappa-opioid receptor agonist, on neuroendocrine function in man.

Authors:  E Ur; D M Wright; P M Bouloux; A Grossman
Journal:  Br J Pharmacol       Date:  1997-03       Impact factor: 8.739

Review 3.  The dynorphin/κ-opioid receptor system and its role in psychiatric disorders.

Authors:  H A Tejeda; T S Shippenberg; R Henriksson
Journal:  Cell Mol Life Sci       Date:  2011-10-16       Impact factor: 9.261

4.  Use of Salvia divinorum in a nationally representative sample.

Authors:  Brian E Perron; Brian K Ahmedani; Michael G Vaughn; Joseph E Glass; Arnelyn Abdon; Li-Tzy Wu
Journal:  Am J Drug Alcohol Abuse       Date:  2011-08-11       Impact factor: 3.829

5.  Evaluation of the transport, in vitro metabolism and pharmacokinetics of Salvinorin A, a potent hallucinogen.

Authors:  Zeynep S Teksin; Insong J Lee; Noble N Nemieboka; Ahmed A Othman; Vijay V Upreti; Hazem E Hassan; Shariq S Syed; Thomas E Prisinzano; Natalie D Eddington
Journal:  Eur J Pharm Biopharm       Date:  2009-06       Impact factor: 5.571

6.  The subjective experience of acute, experimentally-induced Salvia divinorum inebriation.

Authors:  Peter H Addy; Albert Garcia-Romeu; Matthew Metzger; Jenny Wade
Journal:  J Psychopharmacol       Date:  2015-02-17       Impact factor: 4.153

7.  Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.

Authors:  Mohini Ranganathan; Ashley Schnakenberg; Patrick D Skosnik; Bruce M Cohen; Brian Pittman; R Andrew Sewell; Deepak Cyril D'Souza
Journal:  Biol Psychiatry       Date:  2012-07-18       Impact factor: 13.382

8.  Pharmacokinetics of the plant-derived kappa-opioid hallucinogen salvinorin A in nonhuman primates.

Authors:  Matthew D Schmidt; Mark S Schmidt; Eduardo R Butelman; Wayne W Harding; Kevin Tidgewell; Daryl J Murry; Mary Jeanne Kreek; Thomas E Prisinzano
Journal:  Synapse       Date:  2005-12-01       Impact factor: 2.562

9.  Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.).

Authors:  L J Valdés; J L Díaz; A G Paul
Journal:  J Ethnopharmacol       Date:  1983-05       Impact factor: 4.360

Review 10.  Interactions between kappa opioid agonists and cocaine. Preclinical studies.

Authors:  N K Mello; S S Negus
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

View more
  7 in total

Review 1.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

2.  Modular Approach to pseudo-Neoclerodanes as Designer κ-Opioid Ligands.

Authors:  Alexander M Sherwood; Samuel E Williamson; Rachel S Crowley; Logan M Abbott; Victor W Day; Thomas E Prisinzano
Journal:  Org Lett       Date:  2017-09-14       Impact factor: 6.005

3.  Preclinical Testing of Nalfurafine as an Opioid-sparing Adjuvant that Potentiates Analgesia by the Mu Opioid Receptor-targeting Agonist Morphine.

Authors:  Shane W Kaski; Allison N White; Joshua D Gross; Kristen R Trexler; Kim Wix; Aubrie A Harland; Thomas E Prisinzano; Jeffrey Aubé; Steven G Kinsey; Terry Kenakin; David P Siderovski; Vincent Setola
Journal:  J Pharmacol Exp Ther       Date:  2019-09-06       Impact factor: 4.030

Review 4.  Chemical syntheses of the salvinorin chemotype of KOR agonist.

Authors:  Sarah J Hill; Aurélien U C M Brion; Ryan A Shenvi
Journal:  Nat Prod Rep       Date:  2020-11-18       Impact factor: 13.423

5.  Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans.

Authors:  Ana Elda Maqueda; Marta Valle; Peter H Addy; Rosa Maria Antonijoan; Montserrat Puntes; Jimena Coimbra; Maria Rosa Ballester; Maite Garrido; Mireia González; Judit Claramunt; Steven Barker; Izabela Lomnicka; Marian Waguespack; Matthew W Johnson; Roland R Griffiths; Jordi Riba
Journal:  Int J Neuropsychopharmacol       Date:  2016-07-05       Impact factor: 5.176

6.  Salvinorin A Inhibits Airway Hyperreactivity Induced by Ovalbumin Sensitization.

Authors:  Antonietta Rossi; Elisabetta Caiazzo; Rossella Bilancia; Maria A Riemma; Ester Pagano; Carla Cicala; Armando Ialenti; Jordan K Zjawiony; Angelo A Izzo; Raffaele Capasso; Fiorentina Roviezzo
Journal:  Front Pharmacol       Date:  2017-01-13       Impact factor: 5.810

Review 7.  Pharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects.

Authors:  Andreia Machado Brito-da-Costa; Diana Dias-da-Silva; Nelson G M Gomes; Ricardo Jorge Dinis-Oliveira; Áurea Madureira-Carvalho
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.